A Multicenter Randomized Parallel-group Study to Investigate the Efficacy of a Combination of Rosuvastatin and Fenofibrate in the Patients With Diabetes or Atherosclerotic Vascular Diseases With Metabolic Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Diabetic patients have an excess risk of mortality due to cardiovascular diseases (CVD) compared to non-diabetics. Cardiovascular disease mortality rate is reportedly on the rise in several countries in the region, including urban China, Malaysia, Korea and Taiwan. Cardiovascular diseases and stroke are always the number 2 and 3 killers for Taiwanese population in recent years, and they really cost much from our medical resource. For treating dyslipidemia, one of the major risk factor for CVD, statins have been well documented to reduce CV deaths both for primary and secondary prevention in several large-scale trials. It has been reported that the clinical benefits of treating dyslipidemia in patients with diabetes mellitus should be at least equivalent to the benefits observed among those with cardiovascular disease. A meta-analysis of seven trials of statins found that treatment for about 5 years resulted in a 25% reduction in the combined outcome of coronary heart disease death and non-fatal myocardial infarction. Fibrates are another group of hypolipidemic drugs that regulate lipid metabolism and are used quite often in daily practice for diabetic dyslipidemia, because of its beneficial effect to reduce high TG and increase low HDL-C, which are the characteristic lipid abnormalities commonly seen in the patients with diabetes or metabolic syndrome. However, in recently published FIELD study, fenofibrate did not significantly reduce the risk of the primary outcome of coronary events in 9,795 participants with type 2 diabetes mellitus. The higher rate of starting statin therapy in patients allocated placebo might have masked a moderately larger treatment benefit. Furthermore, all the treatment trials to back up the lipid treatment guideline were conducted in Caucasians and no data about the combination therapy with fibrate and statin was published before.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes CVD

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

CV (cardiovascular) MI (myocardial infarction) fenofibrate rosuvastatin this trial is to test the hypothesis that the addition of fenofibrate on rosuvastatin would provide a further reduction in the time

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rosuvastatin,SFC fenofibrate

1. Rosuvastatin 10 mg once daily
2. Rosuvastatin 5 mg + SFC fenofibrate 160 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* previous intolerance to statin or fibrate in low or high doses,
* liver enzyme levels more than 3 times the upper limit of normal,
* pregnancy or breastfeeding,
* nephrotic syndrome,
* uncontrolled diabetes mellitus (HbA1c \> 9),
* uncontrolled hypothyroidism,
* plasma LDL-C level higher than 190 mg/dL or triglyceride level higher than 500 mg/dL,
* coronary heart disease event or revascularisation within a month, congestive heart failure (New York Heart Association classification IIIb or IV),
* hemodynamically important valvular heart disease, gastrointestinal conditions affecting absorption of drugs,
* treatment with other drugs that seriously affect the pharmacokinetics of statins or fibrate,
* unexplained creatine phosphokinase concentrations six or more times the upper limit of normal,
* life-threatening malignancy,
* treatment with immuno suppressive or other lipid lowering drugs.
* Patients previously treated with monotherapy with statins or fibrates will be qualified if they have not already had titration to a dose higher than the equivalent of 5 mg/d of rosuvastatin or 80 mg/d of SFC fenofibrate.

Minimum Eligible Age

20 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

chau chung wu, Phd

Role: CONTACT

Phone: +886-2-23123456

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

200711014M

Identifier Type: -

Identifier Source: org_study_id